依奇珠单抗对比富马酸酯和甲氨蝶呤治疗中重度斑块状银屑病:24周多中心随机开放标签平行组研究
该研究为24周多中心随机开放标签平行组试验,纳入未接受过系统性治疗的中重度斑块状银屑病患者(每组54例),比较依奇珠单抗与富马酸酯(FAEs)及甲氨蝶呤的疗效与安全性。关键次要终点PASI 90/100、sPGA(0,1)及DLQI(0,1)亦均优于对照组。
要点
- 依奇珠单抗24周PASI 75达91%,优于FAEs的22%和甲氨蝶呤的70%。
- PASI 90/100及sPGA、DLQI应答依奇珠单抗亦显著优于两种传统一线治疗。
- 三种治疗安全性特征与既往研究一致。
核心结论
- 在未接受过系统性治疗的中重度斑块状银屑病患者中,依奇珠单抗24周诱导PASI 75/90/100、sPGA(0,1)及DLQI(0,1)应答均优于甲氨蝶呤和FAEs。
研究设计与样本
- 多中心、随机、开放标签、平行组、评估者盲法试验,每组54例未接受过系统性治疗的中重度斑块状银屑病患者。
- 主要终点为24周达到PASI 75的患者比例;关键次要终点包括24周PASI 90、PASI 100、sPGA评分0或1及DLQI评分0或1。
- 安全性事件采用Fisher精确检验分析,缺失数据采用无应答者填补。
主要发现
- 依奇珠单抗组sPGA(0,1)及DLQI(0,1)应答亦优于FAEs和甲氨蝶呤。
- 三种治疗的安全性特征与既往研究一致。
临床怎么用
- 对于未接受过系统性治疗的中重度斑块状银屑病患者,依奇珠单抗在24周诱导深度缓解和生活质量改善方面优于甲氨蝶呤和FAEs。
- 临床选择一线系统治疗时,可参考本头对头试验数据,结合患者个体情况权衡疗效与安全性。
局限性
- 开放标签设计可能影响主观终点评估,但采用评估者盲法。
- 研究周期为24周,缺乏长期疗效与安全性数据。
- 样本量每组54例,对罕见安全性事件的检出效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin-17 antagonists have received a first-line label for moderate-to-severe plaque psoriasis. OBJECTIVES: We conducted the first head-to-head trial between the two most commonly used first-line therapies in Germany, fumaric acid esters (FAEs) and methotrexate, and the interleukin-17A antagonist, ixekizumab. METHODS: Systemic-naive patients were randomized in this parallel-group, active-comparator, open-label, rater-blinded trial (each group n = 54). The primary outcome was the proportion of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) at 24 weeks. Key secondary outcomes included 24-week PASI 90 and 100, static Physician's Global Assessment (sPGA) score of 0 or 1, and Dermatology Life Quality Index (DLQI) score of 0 or 1. Safety events at week 24 were analysed using Fisher's exact test. Missing data were imputed using nonresponder imputation. The trial was registered at ClinicalTrials.gov (NCT02634801) and EudraCT (2015-002649-69). RESULTS: At week 24, more ixekizumab-treated patients achieved PASI 75 [91% vs. 22% FAEs (P < 0·001) and 70% methotrexate (P = 0·014)], PASI 90 [80% vs. 9% FAEs (P < 0·001) and 39% methotrexate (P < 0·001)] and PASI 100 [41% vs. 4% FAEs (P < 0·001) and 13% methotrexate (P = 0·0041)], as well as sPGA (0,1) and DLQI (0,1). CONCLUSIONS: Ixekizumab was superior in inducing PASI 75/90/100, sPGA (0,1) and DLQI (0,1) responses at week 24 compared with methotrexate and FAEs. Safety profiles for all treatments were consistent with prior studies.
引用
- Reich K, Augustin M, Thaçi D, et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. 2019. PMID: 31376153. doi:10.1111/bjd.18384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。